

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA

















